Peaks of Interest
American Chemical Society Honors Brian Bidlingmeyer
American Chemical Society Honors Brian Bidlingmeyer
The American Chemical Society (ACS) named Brian Bidlingmeyer of Agilent Technologies, Inc. (Santa Clara, California) and a member of LCGC's editorial advisory board to the 2012 class of ACS Fellows, a prestigious honor bestowed upon 96 distinguished scientists who have demonstrated outstanding accomplishments in chemistry and made important contributions to ACS, the world's largest scientific society.
"These chemists hold the future to our country, to our way of life, and to the legacy we will leave for the next generation," said ACS President Bassam Z. Shakhashiri, PhD. "Whether it's producing renewable fuels, finding cures for afflictions such as diabetes, cancer, AIDS, and Alzheimer's disease, or ensuring safe drinking water, these Fellows are scientific leaders, improving our lives through the transforming power of chemistry."
The 2012 Fellows were recognized at an induction ceremony during the society's 244th National Meeting and Exposition in Philadelphia, Pennsylvania, where each Fellow received a lapel pin and a certificate.
The ACS Fellows program was created by the ACS Board of Directors in December 2008 "to recognize members of ACS for outstanding achievements in and contributions to science, the profession, and the society." Fellows are chosen from academe, industry, and government.
Agilent Partners with Sera Prognostics to Target Pregnancy Complications
Agilent Technologies and Sera Prognostics (Salt Lake City, Utah) have formed a strategic partnership to develop proteomic assays for the prediction of pregnancy complications. Sera Prognostics is a private biotechnology company that develops diagnostic tests for these risks.
"By providing pivotal information to physicians, Sera's preterm birth predictor is designed to address an unmet medical need for a reliable, early risk assessment that has the potential to help significantly improve the health of mothers and newborns, while materially reducing the costs of care," commented Gregory C. Critchfield, chairman and chief executive officer of Sera Prognostics. "Our partnership with Agilent provides Sera with access to advanced and innovative technologies designed to deliver on the promise of personalized medicine."
Through the partnership with Agilent, Sera Prognostics has purchased a number of liquid chromatography instruments. Furthermore, Sera Prognostics is adapting sample preparation technology from Agilent to meet the demands of high-volume testing.
"Agilent and Sera Prognostics share the vision of applying the power of advanced proteomic technologies to address meaningful medical challenges," said Yvonne Linney, vice president and general manager of Agilent's Life Science Solutions Division.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
Inside the Laboratory: The Richardson Group at the University of South Carolina
November 20th 2024In this edition of “Inside the Laboratory,” Susan Richardson of the University of South Carolina discusses her laboratory’s work with using electron ionization and chemical ionization with gas chromatography–mass spectrometry (GC–MS) to detect DBPs in complex environmental matrices, and how her work advances environmental analysis.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
Infographic: Be confidently audit ready, at any time and reduce failures in pharma QC testing
November 20th 2024Discover how you can simplify the audit preparation process with data integrity dashboards that provide transparency to key actions, and seamlessly track long-term trends and patterns, helping to prevent system suitability failures before they occur with waters_connect Data Intelligence software.
Critical Role of Oligonucleotides in Drug Development Highlighted at EAS Session
November 19th 2024A Monday session at the Eastern Analytical Symposium, sponsored by the Chinese American Chromatography Association, explored key challenges and solutions for achieving more sensitive oligonucleotide analysis.
